Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111319 · ClinicalTrials.gov registry record · Phase 3
VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma
A Phase 3 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00111319: Completed Phase 3 study, sponsored by Millennium Pharmaceuticals.
NCT00111319 is a Phase 3 study that has completed, run by Millennium Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00111319, a Phase 3 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The primary reason for this study is to determine whether the addition of VELCADE (bortezomib) for injection to standard melphalan/prednisone (MP) therapy improves the time to disease progression (TTP) in subjects with previously untreated multiple myeloma.
Interventions
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-12 |
| Phase | Phase 3 |
What the finished NCT00111319 record still lists
NCT00111319 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which bortezomib is the first listed.
NCT00111319 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00111319 about?
NCT00111319 is a clinical study titled "VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma". The primary reason for this study is to determine whether the addition of VELCADE (bortezomib) for injection to standard melphalan/prednisone (MP) therapy improves the time to disease progression (TTP) in subjects with previously untreated multiple myeloma.
What is the current status of trial NCT00111319?
This trial is currently completed. It is a Phase 3 study. The study started on 2004-12.
What interventions are being tested in trial NCT00111319?
The interventions under investigation include: bortezomib (DRUG).
Who is sponsoring clinical trial NCT00111319?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia